| Clinical data | |
|---|---|
| Other names | AB-521 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H17F4NO3S |
| Molar mass | 439.42 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Casdatifan is an investigational new drug that is being evaluated by Arcus Biosciences and AstraZeneca for the treatment of renal cell carcinoma. It is an inhibitor of endothelial PAS domain-containing protein 1 (HIF‑2α).
Casdatifan is allosteric HIF‑2α inhibitor with low-nanomolar potency in cell-based reporter assays.
Casdatifan in combination with cabozantinib (a tyrosine-kinase inhibitor) is currently in phase 3 clinical trials for the treatment of advanced clear cell renal cell carcinoma.